Sponsor

Clinical trials sponsored by Novo Nordisk A/S

Active studies whose public registry record names Novo Nordisk A/S as lead sponsor.

71active studies

36recruiting now

40countries represented

838largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Diabetes Mellitus, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Brazil74 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07533175See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowPhase 1

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Overweight, ObesityCondition

NNC0487-0111, PlaceboTreatment

Denmark, Netherlands2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-02 · NCT07757087See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)Condition

NNC6022-0004, PlaceboTreatment

Netherlands1 locations

Novo Nordisk A/SSponsor

Updated 2026-09-01 · NCT07693868See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Obesity, Type 2 DiabetesCondition

Cagrisema, SemaglutideTreatment

Argentina, Australia303 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07564414See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-08-27 · NCT07503210See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

Overweight, ObesityCondition

UBT251, Oral contraceptiveTreatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07710729See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Obesity, Heart FailureCondition

NNC0487-0111, PlaceboTreatment

Argentina, Australia838 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07567001See eligibility →

Recruiting nowPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Overweight, ObesityCondition

Semaglutide, PlaceboTreatment

Belgium, Bulgaria62 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07770841See eligibility →

Recruiting nowPhase 1

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Obesity, OverweightCondition

UBT251, Cocktail (Warfarin/Caffeine/Midazolam)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07710768See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 1

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Obesity, OverweightCondition

NNC0113-5840, PlaceboTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07566390See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC6989-0001, Placebo (NNC6989-0001)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-07-29 · NCT07437079See eligibility →

Recruiting nowPhase 1

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

ObesityCondition

Liraglutide, Oral SemaglutideTreatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-07-21 · NCT07225816See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowPhase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07339423See eligibility →

Recruiting nowPhase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Obesity, OverweightCondition

Cagrilintide D, Cagrilintide B and placebo semaglutide ITreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-26 · NCT07597018See eligibility →

Recruiting nowPhase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Obesity, OverweightCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

United States11 locations

Novo Nordisk A/SSponsor

Updated 2026-06-25 · NCT07607587See eligibility →

Recruiting nowPhase 1

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

Type 1 Diabetes (T1D), OverweightCondition

NNC0497-0040, PlaceboTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-04 · NCT07578584See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Overweight, ObesityCondition

Cagrilintide, Placebo CagrilintideTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-15 · NCT07557953See eligibility →

Recruiting nowPhase 1

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

ObesityCondition

Cagrilintide, SemaglutideTreatment

Denmark1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-07 · NCT07527195See eligibility →

Recruiting nowPhase 1

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-27 · NCT07508020See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Overweight, ObesityCondition

NNC0662-0419, Oral contraceptiveTreatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-24 · NCT07525791See eligibility →

Recruiting nowPhase 2

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Overweight, ObesityCondition

UBT251, PlaceboTreatment

Canada, United States3 locations

Novo Nordisk A/SSponsor

Updated 2026-04-21 · NCT07395687See eligibility →

Recruiting nowPhase 1

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Overweight, ObeseCondition

Glucose-dependent Insulinotropic Polypeptide (GIP), CagrilintideTreatment

United Kingdom1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-13 · NCT07411560See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney DiseaseCondition

NNC0519-0130, PlaceboTreatment

Argentina, Australia147 locations

Novo Nordisk A/SSponsor

Updated 2026-03-11 · NCT06717698See eligibility →

Recruiting nowPhase 1

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

ObesityCondition

INV-347Treatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-03-06 · NCT07153172See eligibility →

Recruiting nowPhase 1

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

ObesityCondition

CagriSema (Cagrilintide B + semaglutide I), Low Energy DietTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2025-10-08 · NCT07184086See eligibility →

Recruiting nowPhase 1

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

ObesityCondition

Cagrilintide, SemaglutideTreatment

Denmark1 locations

Novo Nordisk A/SSponsor

Updated 2025-07-25 · NCT07010432See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Opening soonPhase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Obesity, OverweightCondition

Zenagamtide, Placebo ( matched to Zenagamtide)Treatment

India, Japan44 locations

Novo Nordisk A/SSponsor

Updated 2026-08-24 · NCT07668401See eligibility →

Opening soonNot applicable

A Retrospective Real-World Cohort Study

Obesity, Type 2 Diabetes (T2D)Condition

No treatment givenTreatment

Denmark1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-24 · NCT07781371See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Opening soonPhase 1

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function

Overweight, ObesityCondition

NNC0487-0111Treatment

Slovakia2 locations

Novo Nordisk A/SSponsor

Updated 2026-05-14 · NCT07587710See eligibility →

Opening soonPhase 3

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Obesity, OverweightCondition

NNC0487-0111, SemaglutideTreatment

Argentina, Brazil120 locations

Novo Nordisk A/SSponsor

Updated 2026-03-12 · NCT07400107See eligibility →

Opening soonNot applicable

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2Condition

SemaglutideTreatment

Locations pending0 locations

Novo Nordisk A/SSponsor

Updated 2025-12-05 · NCT05714683See eligibility →

Invitation onlyNot applicable

Cities for Better Health Childhood Obesity Prevention Initiative

ObesityCondition

Community-based intervention packagesTreatment

Australia, Brazil6 locations

Novo Nordisk A/SSponsor

Updated 2026-08-21 · NCT06855563See eligibility →

Invitation onlyNot applicable

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

ObesityCondition

SemaglutideTreatment

Spain, Switzerland30 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07055607See eligibility →

Invitation onlyNot applicable

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Pregnancy, ObesityCondition

No InterventionTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-07-21 · NCT05503927See eligibility →

Invitation onlyNot applicable

Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

Diabetes Mellitus, Type 2, ObesityCondition

No treatment givenTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-29 · NCT07673822See eligibility →

Invitation onlyNot applicable

A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

Type 2 DiabetesCondition

Intervention not listedTreatment

China1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-20 · NCT07456774See eligibility →

Invitation onlyNot applicable

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2Condition

SemaglutideTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-05 · NCT05689372See eligibility →

Invitation onlyNot applicable

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Pregnancy, ObesityCondition

No InterventionTreatment

Spain, United Kingdom3 locations

Novo Nordisk A/SSponsor

Updated 2026-01-14 · NCT05872022See eligibility →

Invitation onlyNot applicable

WEgovy Real World Assessment of Weight Loss in Korea

ObesityCondition

SemaglutideTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2025-12-12 · NCT07280221See eligibility →

Invitation onlyNot applicable

Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

ObesityCondition

No treatment givenTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2025-11-25 · NCT07154238See eligibility →

Invitation onlyNot applicable

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

Obesity and OverweightCondition

semaglutideTreatment

South Korea8 locations

Novo Nordisk A/SSponsor

Updated 2025-06-12 · NCT07018544See eligibility →

Invitation onlyNot applicable

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Diabetes, Diabetes Mellitus, Type 2Condition

No treatment givenTreatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2023-06-13 · NCT01511393See eligibility →

Active, not recruitingPhase 3

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic SteatohepatitisCondition

Semaglutide, PlaceboTreatment

Argentina, Australia558 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT04822181See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight, ObesityCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

Argentina, Canada67 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07220759See eligibility →

Active, not recruitingPhase 3

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Cardiovascular DiseaseCondition

Cagrilintide, SemaglutideTreatment

Argentina, Australia633 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT05669755See eligibility →

Active, not recruitingPhase 3

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

ObesityCondition

Cagrilintide, SemaglutideTreatment

Argentina, Australia256 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT05567796See eligibility →

Active, not recruitingPhase 1

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

Obesity, OverweightCondition

NNC0638-0355, Placebo (NNC0638-0355)Treatment

Netherlands, United States4 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT06577766See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related sponsors

Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.